USASGP▼
SpyGlass Pharma reports Q2 GAAP EPS of -$0.59
SpyGlass Pharma reported a second-quarter GAAP net loss of $0.59 per share. Research and development expenses rose to $10.94 million from $7.33 million in the same quarter last year, while general and administrative expenses increased to $11.03 million from $1.96 million. The company held $234.20 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which it expects will fund operations through 2028.